ArticleInternational journal of clinical oncology2021

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.

Shigenori Kadowaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.